11 completed, 4 active not recruiting, 3 recruiting, 2 terminated. 23 Phase 3, 6 Phase 2.
Follow Dasatinib: new trials by email Literature Review of Dasatinib trials Research Report on Dasatinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of ELVN-001 Versus Investigator-Selected TKI, in CP-CML Previously Treated With One or More TKIs ELVN-001, TKI - Chronic Myeloid Leukemia (CML), Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive | Phase 3 | Recruiting | Enliven Therapeutics | 450 | 2026-12-31 | 2026-11-18 |
| A Study of HS-10382 Versus Investigator-selected TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP HS-10382, Imatinib, Dasatinib - Chronic Myeloid Leukemia | Phase 3 | Not yet recruiting | Jiangsu Hansoh Pharmaceutical Co., Ltd. | 408 | 2026-12-01 | 2026-10-21 |
| Newly-diagnosed Pediatric T-cell ALL Protocol Venetoclax, Dasatinib, homoharringtonine - Acute Lymphoblastic Leukemia, Childhood Leukemia, Acute Lymphoblastic | Phase 2 / Phase 3 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 610 | 2025-03-11 | 2025-08-26 |
| Single Nuclei RNA-seq to Map Adipose Cellular Populations and Senescent Cells in Older Subjects Lifestyle Intervention, Dasatinib 100 MG, Quercetin 1000mg - Obesity, Healthy Lifestyle | Phase 2 / Phase 3 | Recruiting | Cedars-Sinai Medical Center | 160 | 2023-10-17 | 2026-03-18 |
| A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP Imatinib, Nilotinib, Bosutinib - Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive | Phase 3 | Active not recruiting | Novartis Pharmaceuticals | 405 | 2021-10-06 | 2026-08-28 |
| Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration and Biopsy - B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 | Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 348 | 2021-01-25 | 2026-11-12 |
| Dasatinib Versus Nilotinib for Treatment Naïve Chronic Myeloid Leukemia Dasatinib 100 MG [Sprycel], Nilotinib 150mg oral capsule [Tasigna] - Chronic Myeloid Leukemia - Chronic Phase | Phase 3 | Terminated | Hamad Medical Corporation | 10 | 2017-08-03 | 2019-01-23 |
| Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma Prednisone, Vincristine, Daunorubicin - Acute Lymphoblastic Leukemia, Acute Lymphoblastic Lymphoma | Phase 2 / Phase 3 | Active not recruiting | St. Jude Children's Research Hospital | 790 | 2017-03-29 | 2026-06-17 |
| Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents Pegaspargase, Erwinia asparaginase, Cyclophosphamide - Acute Lymphoblastic Leukemia, Pediatric | Phase 3 | Active not recruiting | Dana-Farber Cancer Institute | 560 | 2017-03-03 | 2026-07-16 |
| Dasatinib Holiday for Improved Tolerability dasatinib (SPRYCEL®) - Myeloid Leukemia, Chronic | Phase 3 | Completed | University of Jena | 291 | 2016-08-01 | 2023-05-10 |
| Precision Diagnosis Directing HDACi and TKI Target Therapy for Adult Ph-like ALL Chidamide, Dasatinib - Leukemia, Leukemia, Acute | Phase 2 / Phase 3 | Unknown | Nanfang Hospital, Southern Medical University | 120 | 2016-02-14 | 2022-07-01 |
| Optimization of TKIs Treatment and Quality of Life in Ph+ CML Patients ≥60 Years in Deep Molecular Response imatinib, nilotinib, dasatinib - Leukemia, Chronic Myeloid | Phase 3 | Completed | Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia | 229 | 2015-06-10 | 2024-08-13 |
| Randomized Phase III Study of Intensive Chemotherapy With or Without Dasatinib (Sprycel™) Dasatinib, Cytarabine, Daunorubicin - Acute Myeloid Leukemia (AML) | Phase 3 | Completed | University of Ulm | 204 | 2014-07-01 | 2024-02-23 |
| Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations Clofarabine, Cyclophosphamide, Cytarabine - B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, BCR-ABL1-Like | Phase 3 | Completed | National Cancer Institute (NCI) | 5949 | 2012-02-29 | 2026-06-02 |
| Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer Placebo, Dasatinib, Docetaxel - Prostatic Neoplasms | Phase 3 | Completed | Bristol-Myers Squibb | 1930 | 2008-10-01 | 2016-10-17 |
| Comparison of Imatinib Versus Dasatinib in Patients With Newly-diagnosed Chronic Phase Chronic Myeloid Leukaemia Imatinib, Dasatinib - Myeloid Leukemia, Chronic, Chronic Phase | Phase 3 | Completed | Newcastle University | 814 | 2008-08-01 | 2018-04-24 |
| Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Asparaginase, Cyclophosphamide, Cytarabine - Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 | Phase 2 / Phase 3 | Completed | National Cancer Institute (NCI) | 63 | 2008-07-14 | 2020-04-13 |
| Total Therapy Study XVI for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia Prednisone, Vincristine, Daunorubicin, PEG-L-asparaginase, Erwinia L-asparaginase, Doxorubicin, Cyclophosphamide, Cytarabine, Thioguanine, Clofarabine, Methotrexate, Mercaptopurine, Dexamethasone, Etoposide, Dasatinib - Acute Lymphoblastic Leukemia | Phase 3 | Completed | St. Jude Children's Research Hospital | 600 | 2007-10-29 | 2022-08-23 |
| A Phase III Study of Dasatinib vs Imatinib in Patients With Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Dasatinib, Imatinib - Myeloid Leukemia, Chronic | Phase 3 | Completed | Bristol-Myers Squibb | 547 | 2007-09-01 | 2017-02-15 |
| A Study of Dasatinib vs. High-Dose Imatinib (600 mg) in Patients With Chronic Phase Chronic Myeloid Leukemia (CML) Who Failed to Achieve Complete Cytogenetic Response After 3-18 Months of Imatinib Therapy Dasatinib, Imatinib - Leukemia | Phase 3 | Terminated | Bristol-Myers Squibb | 3 | 2007-04-01 | 2009-11-20 |
Showing 20 of 23. Sign in to see all of them.
Precursor Cell Lymphoblastic Leukemia-Lymphoma (8) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (7) · Leukemia (5) · Leukemia, Myeloid, Chronic-Phase (5) · Bronchiolitis Obliterans Syndrome (2) · Philadelphia Chromosome (2) · Burkitt Lymphoma (1) · Leukemia, B-Cell (1) · Leukemia, Myeloid, Accelerated Phase (1) · Leukemia, Myeloid, Acute (1) · Lymphoma (1) · Obesity (1) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (1) · Prostatic Neoplasms (1)
Bristol-Myers Squibb (6) · National Cancer Institute (NCI) (3) · St. Jude Children's Research Hospital (2) · Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (1) · Cedars-Sinai Medical Center (1) · Dana-Farber Cancer Institute (1) · Enliven Therapeutics (1) · Hamad Medical Corporation (1) · Institute of Hematology & Blood Diseases Hospital, China (1) · Jiangsu Hansoh Pharmaceutical Co., Ltd. (1) · Nanfang Hospital, Southern Medical University (1) · Newcastle University (1) · Novartis Pharmaceuticals (1) · University of Jena (1) · University of Ulm (1)
United States (14) · Australia (8) · Canada (7) · Germany (7) · Italy (7) · Hungary (6) · United Kingdom (6) · Austria (5) · China (5) · Czechia (5) · France (5) · Netherlands (5) · Poland (5) · Russia (5) · South Korea (5)
Andreas Hochhaus, Prof. (1) · Domenico Russo, Professor (1) · Hartmut Doehner, Prof. Dr. (1) · Hiroto Inaba, MD, PhD (1) · Jane Apperley, MD (1) · Melissa Burns, MD (1) · Michael J Burke (1) · Mohamed A Yassin (1) · Nicolas Musi, MD (1) · Richard E Clark, MD (1) · Sima Jeha, MD (1) · Stephen G O'Brien, MD (1) · William B Slayton (1)
PMID 39121442, PMID 16960978, PMID 19369231, PMID 20131302, PMID 20525995, PMID 22160483, PMID 22645182, PMID 23380743, PMID 24211163, PMID 24311723, PMID 24357015, PMID 24569263, PMID 24722180, PMID 24970932, PMID 25087182, PMID 26118315, PMID 27192969, PMID 29020310, PMID 29518185, PMID 29720733, PMID 29812996, PMID 30120281, PMID 31188727, PMID 31612640, PMID 32496902, PMID 33242441, PMID 34170389, PMID 34933343, PMID 36524980, PMID 37890117, PMID 38820078, PMID 39316653, PMID 40905823, PMID 40908865, PMID 41397287, PMID 41469545, PMID 41490515, PMID 41671463, PMID 42154791, PMID 42339511
U10CA098543 (2), 2008 (1), 2023 (1), F32CA141762 (1), P50GM115279 (1), R01AG075684 (1), R01CA090246 (1), R01CA140729 (1), R37CA036401 (1), U10CA180820 (1), U10CA180886 (1)